New England Capital Financial Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
New England Capital Financial Advisors's BMY Position: Q2 2026 in Review
New England Capital Financial Advisors reduced its Bristol-Myers Squibb (BMY) stake by 32% in Q2 2026, selling an estimated $119K and leaving 4,319 shares worth $249K. The position accounts for 0.06% of the portfolio, ranked #58.
New England Capital Financial Advisors first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $466K in Q4 2022. 1,158 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- New England Capital Financial Advisors held 4,319 shares of Bristol-Myers Squibb worth $249K as of Q2 2026.
- New England Capital Financial Advisors sold 2,075 Bristol-Myers Squibb shares in Q2 2026, an estimated $119K.
- Bristol-Myers Squibb made up 0.06% of New England Capital Financial Advisors's portfolio in Q2 2026, its #58 holding.
- New England Capital Financial Advisors first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
- New England Capital Financial Advisors's Bristol-Myers Squibb position peaked at $466K in Q4 2022.
- 1,158 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on New England Capital Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.